
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Click the title above to open the Pharmaceutical Technology 2018 Solid Dosage Supplement in an interactive PDF format.
over 8 years ago
Improving Nanoprecipitation Controlover 8 years ago
A QbD Approach to Shorten Tablet Development Timeover 8 years ago
High Throughput Screening of Excipientsover 8 years ago
Removing the Bitter Taste from Drug Developmentover 8 years ago
Innopharma Bets on Manufacturing 4.0





